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Phosphorylation is involved in numerous neurodegenerative diseases. In particular, alpha-synuclein is
extensively phosphorylated in aggregates in patients suffering from synucleinopathies. However, the
share of this modification in the events that lead to the conversion of alpha-synuclein to aggregated toxic
species needed to be clarified. The rat model that we developed through rAAV2/6-mediated expression of
alpha-synuclein demonstrates a correlation between neurodegeneration and formation of small filamentous
alpha-synuclein aggregates. A mutation preventing phosphorylation (S129A) significantly increases alpha-
synuclein toxicity and leads to enhanced formation of beta-sheet-rich, proteinase K-resistant aggregates,
increased affinity for intracellular membranes, a disarrayed network of neurofilaments and enhanced
alpha-synuclein nuclear localization. The expression of a mutation mimicking phosphorylation (S129D)
does not lead to dopaminergic cell loss. Nevertheless, fewer but larger aggregates are formed, and signals
of apoptosis are also activated in rats expressing the phosphorylation-mimicking form of alpha-synuclein.
These observations strongly suggest that phosphorylation does not play an active role in the accumulation
of cytotoxic pre-inclusion aggregates. Unexpectedly, the study also demonstrates that constitutive
expression of phosphorylation-mimicking forms of alpha-synuclein does not protect from neurodegenera-
tion. The role of phosphorylation at Serine 129 in the early phase of Parkinson’s disease is examined,
which brings new perspective to therapeutic approaches focusing on the modulation of kinases/phospha-
tases activity to control alpha-synuclein toxicity.
INTRODUCTION
Phosphorylation–dephosphorylation is involved in the
regulation of nearly all processes of life. About one-third of
mammalian proteins are covalently bound to phosphate. The
conformational change in the structure of the protein induced
by the binding of a phosphate is responsible for the activation
or deactivation of enzymes and receptors. Phosphorylation also
plays a role in interaction with protein partners and, in some
cases, functions as a signal for degradation. Phosphorylation is
involved in a number of neurodegenerative diseases. In parti-
cular, phosphorylated alpha-synuclein (a-syn) was shown to be
present in aggregates in patients suffering from dementia with
Lewy bodies, from multiple system atrophy, from brain iron
accumulation type I and from Parkinson’s disease (PD) (1–5).
Alpha-syn has generated much interest for its role in PD. It is
persistently found to be the major component of the hallmark
neuronal inclusions named Lewy bodies (6–10), and genetic
mutations of a-syn have been linked to familial forms of parkin-
sonism and associated with idiopathic PD (6,8,10–15). Serine at
position 129 (Ser129) has been identified as the major phosphate
acceptor site of a-syn in PD cases (1,3,5,16–18).
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The occurrence of phosphorylation raises the question of its
share in the events that lead to the conversion of a-syn to toxic
species, particularly in sporadic PD. An ascendant interpret-
ation is that transient protofibrils are the cytotoxic species,
whereas inclusion bodies are the result of a neuronal protective
strategy channeling misfolded toxic load and converting it into
an inert body (19–26). In the present study, single amino acid
mutants of a-syn have been used to address this question.
Ser129 is converted either to an alanine (S129A) with the
aim of abolishing phosphorylation or to a negatively charged
residue, aspartate (S129D), with the aim of mimicking some
of the effects of phosphorylation (27). Although the adequacy
of aspartate as a substitute to reproduce the effects of phos-
phorylation is still discussed and the impact of other character-
istics of the phosphate group, such as its steric hindrance (28)
or conformational changes (29), are still being investigated,
the S129D mutant is being widely used. The impact of these
modifications on the cytotoxic properties of the protein, on
the one hand, and on its aggregation, on the other hand, are
being examined. Conflicting results have been obtained in
vitro and also in vivo between transgenic Drosophila (30)
and recombinant adeno-associated vector (rAAV)-injected
rats expressing these Ser129 variants (31). S129A enhanced
the formation of inclusions and spared Drosophila from neuro-
degeneration, but markedly increased neuronal cell loss in the
substantia nigra (SN) of rats. Likewise, S129D enhanced tox-
icity in Drosophila, whereas dopaminergic neuronal loss was
virtually absent in S129D-injected rats. These divergences
have raised the question of the adequacy of the fly as a
model for PD, in view of its nervous system and its lack of
any endogenous homolog to a-syn (32,33).
The present studywas undertaken to further understand the cel-
lular andmorphological changes responsible for the observed dis-
crepancies between non-phosphorylated and phosphorylated
a-syn. For this purpose, we based our experimental design on
the unilateral stereotaxic injection of rAAV vectors into the SN
of rats. Recombinant pseudotyped rAAV2/6 vectors were engin-
eered to express wild-type (WT) human a-syn as well as human
a-synwith either the S129AorS129Dmutation. In order to assess
the impact of theA30P familialmutation, humanA30Pa-syn and
its S129A and S129D variants were engineered. We provide evi-
dence that the enhanced loss of dopaminergic neurons, already
caused at a low level of expression of the S129A variants,
correlates with increased deposition of small filamentous a-syn
aggregates, increased association of a-syn with intracellular
membranes and neurofilaments and increased nuclear localiz-
ation. Our results indicate that phosphorylation does not play a
role in the formation of pre-Lewybody toxica-syn species.None-
theless, we also show that phosphorylation does not protect from
neurodegeneration, as evidenced by the formation of aggregates
and the activation of markers of apoptosis following the
expression of the phosphorylation-mimicking S129D variants.
RESULTS
Opposed impacts of S129A and S129D on dopaminergic
neuron survival already at a low level of expression
To investigate the pathogenic potency of recombinant pseudo-
typed rAAV2/6-mediated expression of Ser129-mutated
a-syn, we performed unilateral stereotaxic injections of six
vectors, respectively, into one hemisphere of the SN. The
rAAV2/6 vector variants expressed the following forms of
a-syn: human WT protein, human a-syn bearing the A30P
familial mutation and WT or A30P a-syn submitted to site-
directed mutagenesis converting their serine at position 129
either to alanine (S129A) or to aspartate (S129D). Infection
of 293T cells showed that all constructs yielded comparable
levels of expression (Fig. 1A). The use of an antibody specifi-
cally recognizing a-syn phosphorylated at Ser129 (PSer129
antibody) (1) revealed the increased accumulation of mono-
meric and oligomeric forms of a-syn, following transduction
with viral particles coding for intact Ser129 a-syn when com-
pared with a-syn S129A and a-syn S129D (Fig. 1B). Western
blot analyses disclosed mild non-specific binding of the anti-
body, but quantification and normalization to tubulin substan-
tiated the distinctly increased intensity of the monomeric and
oligomeric bands in WT a-syn cell extracts. This was then
confirmed in vivo. PSer129 staining was indeed positive in
the SN of rats injected with intact Ser129 a-syn, whereas no
staining was observed in rats injected with a-syn S129A or
a-syn S129D (Fig. 1C). Infectivity was also evaluated in
vivo, 8 weeks after unilateral injection. AAV vectors pseudo-
typed with a serotype 6 capsid were chosen for their high
tropism for nigral dopaminergic neurons, as revealed by
their extensive colocalization with tyrosine hydroxylase
(TH)-positive neurons (Fig. 1D).
Injection of three increasing doses of rAAV2/6 vectors
coding for WT a-syn yielded a dose-dependent loss, from
11 to 22%, in the number of neurons positive for the
dopaminergic-specific TH marker in the injected SN
(Fig. 1E). We used the same rationale of increasing doses in
our phosphorylation analysis. The S129A mutation dramati-
cally increased the pathology, whereas S129D was less neuro-
toxic, even when the viral preparation was not diluted. The
increase in a-syn S129A toxicity was dose-dependent, reach-
ing a loss of over 70% of TH-positive neurons in rats injected
with non-diluted viral particles. The a-syn WT form displayed
stronger toxicity than the A30P mutant. This difference was
however not statistically significant, and the divergent patterns
of toxicity between intact Ser129, S129A and S129D
were the same in the case of the a-syn WT and A30P
backbones. The loss of dopaminergic neurons was confirmed
by results obtained with VMAT2 (vesicular monoamine
transporter 2) (data not shown). Finally, the optical density
(OD) of dopaminergic fibers projecting to the striatum
decreased by !16% in S129A brains following the injection
of 1.4 # 107 transduction units (TUs) and displayed differ-
ences between the S129 variants similar to those obtained in
the SN (Fig. 1F).
In order to measure the level of expression at which these
events occurred, injected and non-injected SN of three
animals per group were extracted and homogenized. The
total levels of expression of the vectors, when compared
with the level of endogenous a-syn in the non-injected SN,
were evaluated by western blot analyses, with the use of an
antibody recognizing both human and rat a-syn (Fig. 1G).
Quantitative comparison allowed to roughly estimate that the
mean total level of expression of a-syn was double that of
the rat endogenous protein alone.
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Figure 1. S129A mutation markedly enhances a-syn toxicity, whereas it is hindered by S129D mutation, in rats expressing the transgene at a level comparable to
that of the endogenous protein. (A) Expression of a-syn variants in infected 293T cells when compared with non-infected cells. (B) Fifty micrograms of proteins
from non-infected 293T cells and cells infected with either AAV-CMV-a-syn-WT, AAV-CMV-a-syn-WT/S129A or AAV-CMV-a-syn-WT/S129D. The mem-
brane was probed with the PSer129 antibody, which revealed the presence of monomeric (a single 16 kDa band) and oligomeric (four bands between 30 and
40 kDa) forms in cells expressing WT a-syn, when compared with the non-infected S129A and S129D samples. Histograms represent signal intensities, which
were assessed by The Odysseyw Infrared Imaging System detection and normalized to tubulin. (C) Immunostaining showing phosphorylated a-syn in the SN of
rats injected with AAV-CMV-a-syn-A30P and the absence of phosphorylation in rats injected with AAV-CMV-a-syn-A30P/S129A. Magnification in pictures at
the bottom. Scale bars, four pictures on top: 200 mm and two pictures at the bottom: 50 mm. (D) Immunostaining showing neuronal co-expression of a-syn and
TH in the SN of rats 8 weeks post-virus injection. Scale bars: 500 mm. (E) Significant dose-dependent loss of TH-positive neurons following the injection of
1.4 # 107 TUs, 4.4 # 107 Us and non-diluted viral suspensions. Histograms represent the loss of nigral neurons when compared with the contralateral non-
injected hemisphere. The lesion created by the S129A (A) form was significantly more pronounced than that created by the native Ser129 (S) and S129D
forms (D), in the case of both the wild-type backbone (WT) and the A30P backbone (A30P). One-way analysis of variance (103), followed by Scheffe´’s
post hoc test, revealed a main group effect in all cases. Wild-type backbone: 1.4 # 107 TUs (S129 n ¼ 9, S129A n ¼ 8, S129D n ¼ 9) and 4.4 # 107 TUs
(S129 n ¼ 9, S129A n ¼ 9, S129D n ¼ 8). A30P backbone: 1.4 # 107 TUs (S129 n ¼ 4, S129A n ¼ 5, S129D n ¼ 7) and 4.4 # 107 TUs (S129 n ¼ 6,
S129A n ¼ 5, S129D n ¼ 6). As viral titers were not normalized in the experiments with non-diluted vectors, statistical analyses were not performed.
!P , 0.05, !!P , 0.005, #P , 0.0005, ##P , 0.0001 relative to the two other groups, unless indicated otherwise. Data expressed as average+SEM. (F) Com-
parable results were obtained with TH- and VMAT2-immunoreactivity in the striatal terminals, already at a viral dose of 1.4 # 107 TUs. !P , 0.05,
!!P , 0.005, #P , 0.0005, ##P , 0.0001 relative to the two other groups, unless otherwise indicated. Data were expressed as average+SEM. (G) Fifty micro-
grams of total protein from the SN of rats unilaterally injected with either AAV-CMV-a-syn-A30P, AAV-CMV-a-syn-A30P/S129A or
AAV-CMV-a-syn-A30P/S129D. Numbers in red indicate the values of intensity of the a-syn-positive bands normalized to actin, as assessed by The Odysseyw
Infrared Imaging System Detection. The membrane was probed with a sheep anti-a-syn antibody (AB5334P), which allowed comparison of human a-syn levels
of expression with those of the rat endogenous a-syn. NI, non-injected SN.
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Tight correlation between dopaminergic neuronal loss and
formation of small, a-synuclein-positive, b-sheet-rich,
proteinase K-resistant aggregates
The above results prompted us to examine the relation
between the divergent nigral toxicities of S129A and S129D,
on the one hand, and protein aggregation in the SN, on the
other hand. The formation of amyloid protein aggregates
was evaluated by staining with thioflavin S (ThioS) (Fig. 2A
and B). Upon binding to b-pleated sheet structures, this dye
undergoes a shift of its excitation spectrum, resulting in a flu-
orescence signal at 482 nm (34). With an injected dose of
4.4 # 107 TUs, the number of ThioS-positive signals was
about six times higher in the S129A-injected brains than in
the brains injected with intact Ser129 a-syn or with a-syn
S129D (Fig. 2A). Moreover, although the number of these
structures rose in all six groups following the injection of
non-diluted viral preparations, similar differences between
intact Ser129, S129A and S129D persisted. Again, for each
of the Ser129 variants, numbers pertaining to WT, respect-
ively, A30P, were markedly close.
ThioS-positive staining was restricted to the SN, and ThioS
application followed by immunostaining with the use of an anti-
body specifically targeting human a-syn showed that the
b-pleated sheet structures correspond to the human a-syn-
positive pattern of expression (Fig. 2C and D). A closer exam-
ination revealed that in cells presenting ThioS signal, the
pattern of expression of the transgene was less diffuse in
general and highly concentrated at the ThioS-positive spots
(Fig. 2C). Alpha-syn and ThioS co-staining was also positive
in neuronal fibers in the SN (Fig. 2D). These fibers exhibited
the colocalization most prominently in beaded formations
along the fibers. Again, aggregates along neuronal processes
were more abundant in the S129A-injected SN than in the SN
injected with the two other forms.
Staining against human a-syn performed subsequently to
proteinase K (PK) treatment of the brain slices showed a
similar divergence between the Serine-mutant variants
(Fig. 2E). Following digestion of PK-sensitive forms, distinct
dots as well as cells with irregular cytoplasmic staining were
highlighted. S129D-expressing SN submitted to the identical
PK treatment were substantially poorer in PK-resistant
a-syn, when compared with S129A-expressing SN. This was
in agreement with the ThioS-counting results, indicating the
significantly lower amount of b-pleated sheet-rich structures
in the S129D groups.
Immuno-electron microscopy (IEM) analyses of the SN pars
compacta of rats allowed to uphold our results obtained with
ThioS signals counting and PK treatment, on the one hand,
and enabled a comparative morphological analysis of nigral
neurons from the six different groups of rats, on the other
hand. IEM analyses showed that S129A-expressing dopamin-
ergic neurons enclosed numerous a-syn-positive electro-dense
cytoplasmic aggregates (Fig. 3A–C). Higher magnification of
some of these relatively small cytoplasmic, fuzzy and amor-
phous structures indicated the possible presence of filamentous
material. Aggregates appeared also in some dopaminergic
neurons transduced with WT, A30P or both S129D and A30P/
S129D variants, although to a much lesser extent (Fig. 3C).
Fewer but larger aggregates in the case of S129D
Our overall appraisal, with fluorescence microscopy, was that
ThioS-fluorescent structures in the S129D brains were less
numerous, but generally larger in size than those observed in
the other groups (Fig. 4A). In order to examine this observation
in a more quantitative manner, we first scanned with a confocal
microscope up to 110 whole ThioS-positive nigral neurons of
rats injected with the A30P variants. Multichannel, three-
dimensional images of 178 ThioS-positive aggregates were
deconvolved and processed through an image analysis
software of volumetric segmentation, and quantitative data
were extracted with the ImageJ program. As the amplification
of the signal generated by fluorescence is to be taken into
account (34), we did not regard crude values put forth by the
ImageJ computational program as scale-sensitive measures.
Figure 2. ThioS-positive and PK-resistant a-syn species are markedly
enhanced by S129A mutation when compared with S129D mutation. (A) Sig-
nificant dose-dependent increase in ThioS-positive signals following the injec-
tion of 4.4 # 107 TUs and non-diluted viral suspensions. Histograms represent
the number of ThioS-positive aggregates per mm2. One-way analysis of var-
iance (103), followed by Scheffe´’s post hoc test, revealed a main group
effect in all cases. As viral titers were not normalized in the experiments
with non-diluted vectors, statistical analyses were not performed. WT
backbone 4.4 # 107 TUs: [S129 (S) n ¼ 9, S129A (A) n ¼ 9, S129D
(D) n ¼ 7]. WT backbone non-diluted: (S129 n ¼ 4, S129A n ¼ 6,
S129D n ¼ 5). A30P backbone 4.4 # 107 TUs: (S129 n ¼ 6, S129A n ¼ 6,
S129D n ¼ 6). A30P backbone non-diluted: (S129 n ¼ 45, S129A
n ¼ 6, S129D n ¼ 4). ##P , 0.0001 relative to the two other groups. Data
were expressed as average+SEM. (B) Immunostaining showing ThioS
signal (green) in WT-, S129A- and S129D-injected rats, 8 weeks post-virus
injection, when compared with the non-injected (NI) hemisphere. Scale
bars, 50 mm. Inset: magnification of a neuron revealing positive ThioS
signals (green) and the nucleus (Dapi staining, blue). (C) Immunostaining
for ThioS (green) and human a-syn (red) and Dapi staining of the nuclei
(blue). a-syn immunoreactivity is punctate in cells displaying ThioS-positive
signals (arrowheads), when compared with cells without ThioS signals
(arrows). Scale bars, 20 mm. (D) Colocalization of ThioS (green) and
human a-syn (red) within beaded formations in neuritic processes. Scale
bars, upper panels: 20 mm and lower panels: 10 mm. (E) Staining against
human a-syn preceded by PK treatment (þPK) or not (2PK) of adjacent
25 mm slices of S129A- or S129D-injected brains. S129D-expressing SN sub-
mitted to the identical PK treatment were substantially poorer in PK-resistant
a-syn. Scale bars, 50 mm.
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However, as all slices were treated simultaneously under
strictly the same conditions and image acquisition and deconvo-
lution were performed with the exact same parameters, we
could give credence to the relative differences among the
groups. In fact, measures indicated that the mean volume of a
single signal yielded in A30P/S129D-injected animals was
Figure 3. IEM demonstrating a-syn-positive aggregates and extensive nigral human a-syn-positive staining. Numerous a-syn-positive electro-dense cytoplasmic
aggregates (arrows) in the nigral neurons expressing the WT/S129A variant (A) and the A30P/S129A variant (B), mostly positioned in the vicinity of the nucleus
(N) and of tubulo-membranous structures (T)—the ER and the Golgi apparatus. (A) Black arrowheads indicate the lobulation of the nucleus. White arrowheads
indicate stained Golgi cisternae. (B) Box: magnification of a tubulo-membranous structure, probably the ER. (C) Higher magnifications of WT/S129A, A30P/
S129A, WT/S129D and A30P/S129D aggregates. These higher magnifications reveal filamentous material at times (arrows and white box), association with
lysosomes (dark flecks) and with a phagosome-like halo structure containing vesicles. Gold particles are visualized in the filamentous material and near to
the membrane enclosing vesicles (white arrowheads). Scale bars (B): 500 nm and (C): 250 nm.
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1.4- and 2.3-fold that of signals yielded in A30P/S129A and
A30P animals, respectively (Fig. 4B). These data suggest that
the process of aggregation in the case of the S129D variants
differs from that in the case of the other variants.
Subcellular events providing insight into how preventing
phosphorylation enhances the cytotoxicity of a-synuclein
IEM images revealed that aggregated a-syn-positive structures
were frequently associated with lysosomes, which appeared as
dark flecks in the IEM images. These aggregates were often
associated with a round, glassy and unstained phagosome-like
structure. Vesicular content was discernible in some of these
structures (Fig. 3C). IEM also showed that the aggregates pre-
ferentially localized in the perinuclear region and were also
often neighboring intracytoplasmic membranes. This was in
agreement with the results obtained by confocal scanning,
which illustrated that ThioS-positive signals were most fre-
quently arrayed in the vicinity of the nucleus and clearly
marked the indented regions of the irregularly shaped
nucleus (Fig. 5A). S129A- and A30P/S129A-expressing
neurons differed from the other groups, in that they displayed
extensive positive staining in tubulo-membranous structures
(Fig. 3)—the endoplasmic reticulum (ER) and the Golgi
apparatus (Figs 3A and 6A)—as well as in the outer membrane
of the mitochondria (Fig. 6B). Alpha-syn was much less
present in intracellular membranes in the intact Ser129- and
S129D-expressing nigral neurons. In these groups, the associ-
ation of a-syn with the membranous tubular system occurred
only with the formation of aggregated structures. Finally, in
S129A groups, IEM showed a large amount of gold particles
associated with a disarrayed network of neurofilaments in
neuritic fibers (Fig. 6C).
Nuclear localization correlates with enhanced toxicity
of a-synuclein species rather than being
associated with phosphorylation
As phosphorylated a-syn was found to be preferentially loca-
lized in the nuclei of some dopaminergic neurons in synuclei-
nopathy models (35–38), we investigated the existence of a
Figure 4. S129D-expressing rats display larger a-syn-, ThioS-positive aggre-
gates. (A) ThioS signals, colocalizing with a-syn staining, adjoining the
nuclei. ThioS-positive structures in the S129D-injected brains appear gener-
ally larger in size than those observed in S129A-injected brains. Scale bars,
10 mm. (B) Volumetric segmentation analysis of three-dimensional decon-
volved images of 178 ThioS-positive aggregates. The mean volume of a
single signal yielded in A30P/S129D-injected animals was 1.4- and 2.3-fold
that of signals yielded in A30P/S129A and A30P animals, respectively
(A30P-injected rats: n ¼ 4; A30P/S129A-injected rats: n ¼ 6; A30P/
S129D-injected rats: n ¼ 6). #P , 0.05 and ##P , 0.0001. Data were
expressed as average + SEM.
Figure 5. Condensation and lobulation of the a-syn-positive neuronal nuclei.
(A) Confocal images of neurons stained with ThioS (green) and Dapi (blue),
illustrating the condensation and irregularity in shape of cells bearing ThioS-
positive structures. ThioS-positive signals are most frequently arrayed in the
vicinity of the nucleus and clearly mark the indented regions of the irregularly
shaped nucleus. Scale bars, 2 mm. (B) IEM images of neurons within the SN
pars compacta. Note the extensive a-syn-positive staining in-between the lobula-
tions (yellow arrowhead). Rats injected with WT/S129A. Scale bars: 500 nm.
(C) Immunohistological co-staining against lamin-B-positive nuclear mem-
branes (green) and human a-syn (red). Note the correlation between lobulated
nuclei and enhanced punctation in a-syn signals. Scale bars: 5 mm.
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correlation between the phosphorylation status at serine 129
and nuclear localization of the protein. Triple immunostaining
with the use of an antibody specifically recognizing human
a-syn, PSer129 antibody (1) and an antibody recognizing
lamin-B in brains injected with WT or A30P a-syn confirmed
phosphorylation in these rats and disclosed intense fluor-
escence within the nuclei (Fig. 7A and B). Phosphorylated
a-syn was also present in neuronal processes, in which it
accumulated in beaded formations. In S129A- and S129D-
expressing neurons, fluorescent staining with the use of a
phosphorylation-independent antibody against human a-syn
showed expression in the cytoplasm and the nucleus, as well
as in the neuritic processes (Fig. 7C). However, in the
S129A forms, there were more beaded formations in the
fibers and, within the cell body, a-syn’s fluorescence was
more intense in the nucleus, when compared with the other
forms. Strikingly, nuclear staining was also positive in the
S129A-expressing cells analyzed by IEM, which revealed
extensive numbers of gold particles in the S129A neuronal
nuclei when compared with the serine forms and S129D var-
iants (Fig. 7D and E). These observations strongly suggest
that rather than being associated with phosphorylation,
nuclear localization correlates with enhanced toxicity of the
a-syn species.
Activation of Bax and caspase-9 and morphological
characteristics of apoptosis in cells developing aggregates
Ongoing nigral neurodegeneration was demonstrated in the
A30P- and A30P/S129A-injected rats by positive staining
against cleaved caspase-9 and Bax (Fig. 8A and B). Strikingly,
these markers were also activated in the A30P/S129D-
injected rats (Fig. 8C). Co-staining of cleaved caspase-9 and
dopaminergic-specific TH marker showed that the apoptotic
pathway was activated in the remaining dopaminergic
neurons. The activation of these markers of apoptosis sub-
stantiates the assumption that the significant decrease in
TH-positive nigral neurons was due to cell death rather than
to TH down-regulation.
In parallel, we observed morphological markers of apopto-
sis: IEM and immunofluorescence analyses called attention to
the fact that, in all variants, nuclei of neurons displaying
Figure 6. IEM demonstrating labeling of the Golgi apparatus, mitochondria and neurofilaments. (A) Positive staining of the Golgi apparatus. Rats injected with
WT/S129A. Box: magnification of stained cisternae (arrows). (B) Gold particles on the outer membrane of mitochondria. Rats injected with A30P/S129A. (C)
Extensive staining of neurofilaments within a neuritic fiber (arrows) and disarrayed network of stained neurofilaments (white box). Rats injected with WT/
S129A. Scale bars: (A) 500 nm, (B) 250 nm and (C) 200 nm.
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aggregates were condensed and lobulated (Fig. 5). Lobulation
was perceived with the use of lamin-B staining against the
nuclear membrane (Fig. 5C). Remarkably, cells displayed
lobulated nuclei in correlation with punctate a-syn-positive
signals and were less lobulated when a-syn staining was
diffuse. Moreover, confocal images processed through the
ImageJ segmentation software revealed that the mean
volume of nuclei, stained with Dapi, in cells displaying
ThioS signals, was reduced by 40%, and their mean Dapi-
fluorescence intensity was enhanced by 180% when compared
with the nuclei of ThioS-negative neurons.
DISCUSSION
The question of the role of phosphorylation of a-syn in the
pathogenic process of PD remains a debated issue. Various
in vitro and in vivo results are divergent (1,30,31,39–43).
In the present work, we combined several approaches to
explore the cellular events underlying the impact of phos-
phorylation of human WT and A30P a-syn expressed in the
nigral dopaminergic neurons of rats. In agreement with
results obtained in a previous study of rAAV-injected rats
(31), the expression of the phosphorylation-prevented S129A
variants exacerbates a-syn toxicity, whereas the expression
of the phosphorylation-mimicking S129D variants does not
cause dopaminergic deficits.
Our quantitative investigation reveals that significantly
higher numbers of a-syn aggregates are formed in the SN of
rats injected with the most neurotoxic form, S129A, in a dose-
dependent manner and independent of the presence or absence
of the familial A30P mutation. The correlation between dopa-
minergic cell loss and enhanced formation of relatively small
aggregates supports the hypothesis that aggregated a-syn
species, precursors of the characteristic inclusions of PD, are
intimately linked with the progression of nigrostriatal degener-
ation. In line with these observations, S129D-injected animals,
which do not present any significant nigral neuronal loss,
Figure 7. Enhanced nuclear localization of a-synuclein neurotoxic species. (A) Immunostaining with PSer129 antibody reveals enhanced localization in nucleus
as well as accumulation along neural processes. Scale bar: 20 mm. (B) Confocal images of neurons in the SN of rats injected with A30P. Immunohistological
co-staining against human a-syn (red), phosphorylated a-syn (green) and lamin-B (blue). (C) Immunostaining with the phosphorylation-independent antibody
against human a-syn reveals intensified nuclear localization of S129A when compared with S129D. Note the concomitant, widespread presence of S129A in the
fibers. Scale bars: 200 mm. (D and E) IEM images revealing numerous gold particles in the WT/S129A (C) and A30P/S129A (D) neuronal nuclei. Scale bars: (C)
500 nm and (D) 200 nm.
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indeed display a significantly lower amount of aggregates. The
SN of S129D-injected rats are however not devoid of aggre-
gates when compared with the contralateral non-injected SN,
where virtually no signal can be detected.
The above data challenge two recent propositions. First, it
has been proposed by various investigators that the expression
of the S129A mutant protein leads to fewer inclusions
(31,40,43). The present immunohistological and biochemical
analyses reveal that the expression of the S129A mutant leads
to the formation of significantly higher amounts of aggregates.
The aggregates are ThioS-positive, indicating the formation of
b-sheet-rich a-syn aggregated structures in the neuronal cell
body and in processes as well. They are also PK-resistant, and
IEM reveals that they are irregularly shaped, associated with
specific organelles and positioned in the vicinity of the
nucleus. Secondly, the estimation of dopaminergic nigral cell
loss, which is significantly higher following S129A expression,
when compared with S129D expression, has led to the sugges-
tion that phosphorylation protects from neurodegeneration
(31). Evidence is provided here that aggregates are formed
and signals of apoptosis are activated also in rats expressing
the S129D form of a-syn. Hence, phosphorylation-mimicking
variants of a-syn—both the WT form and the A30P mutant—
cannot be considered protective.
The enhanced aggregation and cytotoxicity of the S129A
variants are all the more surprising in view of the well-
described presence of phosphorylated a-syn almost exclu-
sively in the insoluble fraction of synucleinopathic human
brains. The following explanation can be advanced. Phos-
phorylation intervenes in the conversion from fibrils to
inclusion bodies. Preventing phosphorylation hinders the
agglomeration of fibrils into inclusion bodies, thereby
causing the accumulation of the cytotoxic early stage aggre-
gated species. This is supported by our observation that the
few aggregates developed in the S129D groups are larger
than those in the S129A groups. Another possible explanation
is that phosphorylation of a-syn is not a direct cause of path-
ology. Rather, phosphorylated a-syn is detected in inclusions
because, as already shown for some proteins (44–46), phos-
phorylation may act as a signal for elimination. In the patho-
logical situation of PD, the proteolytic machinery of
elimination is impaired. If phosphorylation indeed regulates
the turnover of a-syn, in PD cases, phosphorylated a-syn
accumulates in the cytoplasm, is entrapped in the course of
aggregation and is thus found abundant in the inclusions. In
our model, the expression of the phosphorylation-prevented
S129A variants forestalls the signal for the normal turnover
of the protein. These variants then mediate degeneration via
the formation of toxic pre-inclusion aggregates, via enhanced
affinity for membranes and via nuclear localization.
A closer analysis of a-syn-positive staining and of the
electro-dense aggregates reveals a number of cellular events
and provides a mechanistic insight into the mediation of
acute toxicity by a-syn S129A. Interestingly, these data corre-
spond to cellular events pointed out in post-mortem investi-
gations of human cases and therefore give weight to the
validity of the rAAV-based rodent model of PD expressing
human a-syn (31,38,47–49).
First, we found that dark lysosomal bodies and phagosome-
like glassy bodies are most often trapped in the relatively
small aggregates. In fact, a-syn can be cleared by autophagy
(50–53), and autophagic lysosomal impairment is known to
participate in the amyloidogenic aggregation of a-syn
(51,54–56). Reciprocally, the expression of mutant a-syn in
rat ventral midbrain cultures blocks lysosomal function (51).
The sequestration of lysosomes and phagosomes could be a
consequence of the attempt of cells to remove abnormal aggre-
gated proteins and damaged organelles from the cytoplasm.
Secondly, in our model, we observe the prominent presence
of a-syn in the vicinity of the nucleus, particularly in the
indented regions of the nucleus, and we witness the accumu-
lation of the protein in intracytoplasmic membranes, particu-
larly in tubulo-membranous structures—the ER and Golgi
apparatus. This is in line with the currently dominant hypoth-
esis that phosphorylation of a-syn reduces the interaction of
the protein with phospholipids (1,38,42). This hypothesis,
however, has led some to suggest that decreased affinity of
phosphorylated a-syn for membranes leads to an increase in
the free a-syn pool, thereby contributing to promote its assem-
bly into abnormal filaments in the cytoplasm. We rather
demonstrate the enhanced neurotoxic potential of the
phosphorylation-prevented variants.
On the one hand, our observations described earlier indicate
impairment in ER–Golgi trafficking. Cellular models of PD
Figure 8. Markers of apoptosis are activated. (A) Positive immunostaining
against activated caspase-9 revealed on the injected SN of A30P and A30P/
S129A rats, in contrast to the non-injected side. Scale bars: 200 mm. (B)
Co-immunostaining of activated caspase-9 (green) and Bax (red), as illustrated
here in an A30P rat. Scale bars: 100 mm. (C) Caspase-9 is also activated in
A30P/S129D rats. Co-immunostaining of activated caspase-9 (green) and
TH marker (red). Scale bars: 200 mm.
880 Human Molecular Genetics, 2009, Vol. 18, No. 5
showed that a-syn accumulation correlates with induced
disruption of the ER–Golgi vesicular trafficking and ER
stress (57–59). The pathogenic expression of a-syn has also
been shown to disrupt the ubiquitin-dependent proteasomal
system, which may be responsible for the accumulation of mis-
folded protein in the ER andmay contribute to enhanced vulner-
ability to ER stress. The upregulation of ER stress markers and
fragmentation of the Golgi apparatus were reported in several
human neurodegenerative diseases (60–64). ER stress has
been functionally correlated with accumulated and aggregated
a-syn and identified as a pathogenic event present in dopamin-
ergic neurons of PD cases (57,65,66). Interestingly, a cellular
study of PD reported strong correspondences between pre-
fibrillar aggregate-forming a-syn in the perinuclear region,
Golgi fragmentation and aggregation of intact and active lyso-
somes, mitochondria and autophagosome precursors, at the
inclusion-forming sites (67).
On the other hand, damage of the Golgi apparatus could
result from the impaired, overloaded microtubule-mediated
transport system (68). Indeed, our IEM analysis indicates the
extensive amount of gold particles associated with a disar-
rayed network of neurofilaments in neuronal processes of
S129A-injected rats. We noted also Lewy-like dystrophic
neurites with the appearance of a-syn- and ThioS-positive
beaded formations along neuronal processes. The accumu-
lation of a-syn species along the trafficking system may there-
fore indirectly contribute to Golgi fragmentation, which is
linked to apoptosis (69,70). Consistent with our observations,
post-mortem analyses of PD brains showed that Golgi frag-
mentation is mostly induced in nigral neurons bearing precur-
sors of inclusion bodies, when compared with neurons
containing Lewy bodies (71).
Thirdly, we report, in our S129A model, the association of
a-syn S129A with the outer membrane of mitochondria and
we witness in all variants the activation of Bax and
caspase-9, which are intimately linked to mitochondrial
damage (72). It is reasonable to believe that the presence of
a-syn interferes with the mitochondrial respiratory chain
system. Indeed, a number of in vitro studies have demon-
strated the association of a-syn with mitochondrial mem-
branes (73–75) and have proposed this association has a
pivotal role in the pathogenesis of PD, as it provokes the
release of cytochrome c with the subsequent activation of
caspase cascade and with oxidative damages, eventually
causing apoptosis (72,74). In addition, a recent analysis of
mitochondria from the SN and striatum of post-mortem
late-onset PD brains also reported significant association of
a-syn with mitochondria and with complex I as well as
decreased complex I activity (76). This will be enhanced
when a-syn oligomers and protofibrils are involved. Mito-
chondrial pathology was reported in cell cultures overexpres-
sing a-syn as well as in transgenic mice overexpressing the
A53T a-syn mutant (57,58,61,67,77–80). Mitochondrial
activity was estimated to decrease by 30–40% in the SN of
PD brains (81–84). As for markers of apoptosis, activation
of Bax-dependent pathways and of apoptotic effectors
caspase-3 and -9 has been identified in correlation with
nigral dopaminergic cell loss in PD (85–87). These pathways
contribute to nuclear chromatin condensation and DNA frag-
mentation, which have become morphological hallmarks of
apoptotic degradation (88). Remarkably, we observed in
both S129A- and S129D-injected rats that nuclei of dopamin-
ergic neurons displaying aggregates are condensed and lobu-
lated. Furthermore, susceptibility to a-syn overexpression
appears to be specific to neurons, because IEM analysis
reveals that oligodendroglial cells, which also express
human a-syn, never present lobulated nuclei nor aggregates
(data not shown).
Fourth, our observations indicate that enhanced toxicity of
S129A correlates with intensified nuclear localization. The
detection of intense and diffuse staining in the S129A nuclei
was unexpected in view of studies reporting preferential local-
ization of phosphorylated a-syn in the nucleus of some dopa-
minergic neurons in synucleinopathy models (35–38). Our
results show that it is not phosphorylation that prompts local-
ization to the nucleus. Nuclear localization rather correlates
with enhanced toxicity of a-syn species. In fact, increased
nuclear localization has been associated with increased tox-
icity in PD according to experiments revealing a-syn inter-
action with histones (36,89,90).
In our experimental design, the expression of WT a-syn or
of the a-syn A30P mutant leads to a rather modest loss of
dopaminergic neurons. In order to discuss our results and pos-
ition them with respect to previous studies, we performed
western blot analyses to assess the level of expression, and
we were able to compare values. Our experimental design
leads to an approximate doubling of the total amount of
a-syn in the SN. This result is pertinent in many ways. Alpha-
syn transgenic mice have been described to express 2–15
times the level of the endogenous protein, but none of them
displayed significant nigrostriatal degeneration (7,91–94).
The mild neuropathology in these mouse models has been
explained either by species specificities or by compensatory
responses arising with constitutive overexpression of a-syn
during development, or finally by the assumption that a critical
threshold of a-syn expression is required for triggering nigros-
triatal dopaminergic degeneration and behavioral defects. Our
model demonstrates that the acute induction of a-syn
expression in adult rats, only doubling the nigral expression
of a-syn, is sufficient to trigger significant nigral cell loss. Fur-
thermore, we used lower amounts of viral vectors, leading to a
lower extent of neurodegeneration, for the purpose of avoiding
non-specific effects and inflammatory responses provoked by
an excessive concentration of viral particles. Our results corre-
late with another study (31), in which rAAV injection of WT
a-syn led to an approximately 3.6-fold increase in total a-syn
expression and to !40% loss of TH-positive nigral neurons.
Our rAAV2/6 injection of WT a-syn causes a !20% loss of
TH-positive nigral neurons. It is interesting to note that an
approximate doubling of WT a-syn expression has been
reported in the case of several families with a-syn genomic
multiplication and developing an autosomal-dominant PD
(12,15,95,96). Furthermore, our results show that a doubling
of the total level of a-syn displays higher toxicity than the
A30P missense mutant. In agreement with our observations,
an excess of WT a-syn was reported to have more devastating
consequences than mutant a-syn (12). An approximate dou-
bling in a-syn expression appears to be a major determinant
of the age of onset, the extent of the neurodegenerative
process and the severity of the phenotype (12,15,96,97).
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Our data show that aggregates and morphological character-
istics of cell death are present in all rats—expressing either
phosphorylation-mimicking or phosphorylation-preventing
a-syn variants—although they appear with distinct intensities
or at different paces. We suggest that the different mutant
forms activate mechanisms with distinct dynamic properties.
Besides, phosphorylation of serine at position 87 (Ser87),
which has a critical position within the NAC domain, was
pointed out in vitro (98–100). In vivo analyses of the potential
of phosphorylation at Ser87 may complement the understand-
ing of the impact of this post-translational modification on the
properties of a-syn in PD pathogenesis. The modulation of
phosphorylation of a-syn by the use of kinases or phospha-
tases has been a candidate in the development of therapeutic
tools. Our results bring a new perspective to these strategies
for the treatment of PD. The uncovering of the subcellular
structures involved in the process of neurodegeneration may
also contribute to a better understanding of the important pre-




Human WT and human A30P a-syn genes (nucleotides 46–
520, GenBank accession no. NM_000345) were cloned into
the AAV-CMV-MCS (Stratagene, La Jolla, CA, USA) back-
bone. Single-nucleotide mutations were introduced to the
human WT and A30P a-syn genes using QuickChange Site-
Directed Mutagenesis Kit (Stratagene): replacement of a T
at position 385 of the sequence of human a-syn by a G
yielded an S129A mutation. Replacement of a C at position
386 of the sequence of the S129A variant by an A yielded
an S129D mutation. Primers used for the generation of the
S129A variants were sense: TATGAAATGCCTGCTGAGG
AAGGGTAT and antisense: ATACCCTTCCTCAGCAGG
CATTTCATA and for the generation of S129D variants
were sense: GAAATGCCTGATGAGGAAGG and antisense:
CCTTCCTCATCAGGCATTTC.
rAAV2/6 virus production and titration
The recombinant pseudotyped rAAV2/6 (rAAV2 genome
packaged in the serotype 6 capsid) was produced by
co-transfecting the pAAV-CMV shuttle plasmid coding for
a-syn with the pDF6 packaging plasmid (101). Cell lysate
was subjected to purification by high-performance liquid
chromatography on the HiTrap Heparin column (GE Health-
care Bio-Sciences AB, Uppsala, Sweden). The viral suspen-
sion obtained was concentrated by using Centricon Plus-20
filter units (Regenerated Cellulose 100,000 MWCO; Milli-
pore, Billerica, MA, USA), and the suspension medium was
replaced with phosphate-buffered saline (PBS). The viral
genome (vg) titers were then evaluated. A defined volume of
viral suspension (1 ml) was digested with PK (10 mg/ml) at
558C for 30 min. The number of vg/ml was determined by
real-time polymerase chain reaction (PCR) using a set of
primers specific for a viral sequence in the beta-globin
intron (forward: CGTGCCAAGAGTGACGTAAG and
reverse: TGGTGCAAAGAGGCATGATA). In order to
measure the relative infectivity of all viruses, human embryo-
nic kidney 293T cells were infected with serial dilutions of
viruses. Forty-eight hours later, cells were collected and
total DNA was extracted using DNeasy Blood&Tissue Kit
(Qiagen, Valencia, CA, USA) according to the supplier’s pro-
tocol, including the optional RNase A treatment. Then, in
order to eliminate transcriptionally inactive single-stranded
viral genomes, extracted DNA was treated with S1 nuclease
(Promega, Madison, WI, USA) at a final concentration of
60 U/ml for 30 min at 378C. The enzyme was inactivated for
15 min at 978C. Samples were again purified on DNeasy
columns to remove buffer components that interfere with real-
time PCR reaction. The number of remaining viral genomes
was finally measured by real-time PCR using the beta-globin
primers described earlier. In parallel, the amount of cellular
DNA was determined using a pair of primers specific for
the human albumin gene (forward: TGAAACATACGTT
CCCAAAGAGTTT and reverse: CTCTCCTTCTCAGAAA
GTGTGCATAT). This permitted to take into account the
total input of target cells. Relative infectivity of viruses was
calculated by plotting the logarithm of beta-globin copies (cor-
rected for the albumin content) against the logarithm of virus
dilutions. The plot was used to determine the dilution interval
between viruses, which was subsequently converted into a
relative infectivity ratio. TUs were then estimated by comparison
with a reference AAV vector [AAV-CMV-EGFP (Enhanced
Green Fluorescent Protein)], whose infectivity was determined
by flow cytometry for direct EGFP fluorescence. The percentage
of EGFP-positive cells was determined 48 h after infection of
293T cells, with respect to non-infected control cells and the
number of infection events calculated according to Poisson’s
formula. The estimated titer of the AAV-CMV-EGFP viral
batch was 2 # 1010 TU/ml. The titer measures obtained
were the following: AAV-CMV-a-syn-WT: 1.7 # 1011 TU/ml,
AAV-CMV-a-syn-WT-S129A: 1.2 # 1011 TU/ml, AAV-CMV-
a-syn-WT-S129D: 1.7 # 1011 TU/ml, AAV-CMV-a-syn-
A30P: 0.9 # 1011 TU/ml, AAV-CMV-a-syn-A30P-S129A:
1.9 #1011 TU/ml and AAV-CMV-a-syn-A30P-S129D:
1.4 # 1011TU/ml.
In vitro expression
293T cells were infected with 2 ml of rAAV2/6 vectors, and cel-
lular lysates were harvested 2 days post-infection in lysis buffer
(Tris buffer saline, EDTA 1 mM, Triton X 0.5%, NP40 0.5%)
containing protease inhibitors (Roche Pharma, Basel, Switzer-
land). The lysis buffer included additional okadaic acid
(10 mM) and sodium orthovanadate (0.5 mM) for experiments
to detect the presence of phosphorylated a-syn. Equal
amounts of protein (50 mg) were loaded onto 15% sodium
dodecyl sulfate (SDS)–polyacrylamide gel (PAGE), followed
by the transfer of proteins onto a nitrocellulose membrane
(Bio-Rad, Hercules, CA, USA). A polyclonal antibody gener-
ated against the 101–124 amino acid sequence of human
a-syn was generated and affinity-purified with the immunogen
by Research Genetics (Huntsville, AL, USA) and used to detect
the a-syn protein (1:1000). An anti a-syn phosphorylated at
Ser129 (1) was used to detect phosphorylated a-syn. Equal
total protein load was checked by probing the same membrane
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with an anti-tubulin antibody (1:2000; Sigma, St Louis, MO,
USA). Detection and quantification were performed using the
Odysseyw Infrared Imaging System.
Stereotaxic unilateral injection into the SN of rats
Adult Wistar female rats (Charles River Laboratories, France)
weighing !200 g were housed in 12 h light/dark cycle, with
ad libitum access to food and water, in accordance with the
European Community Council directive (86/609/EEC) for
the care and use of laboratory animals. For stereotaxic injec-
tions, the animals were deeply anesthetized with a mixture
of xylazine/ketamine and placed in the stereotaxic frame
(David Kopf Instruments, Tujunga, CA, USA). Two microli-
ters of viral preparation were injected in the right brain hemi-
sphere of these rats using a 10 ml Hamilton syringe with a
34-gauge blunt tip needle at a speed of 0.2 ml/min, with an
automatic pump (CMA Microdialysis, Sweden). The needle
was left in place for an additional 5 min before being slowly
withdrawn. SN was targeted by using the following anterior,
lateral and ventral coordinates: 5.2, 2.0, 7.8 mm (bregma coor-
dinates) (according to the atlas of Paxinos and Watson).
Human a-synuclein extraction from SN samples
Eight weeks post-injection, three rats per group were sacrificed
using a guillotine. Their brains were then rapidly extracted and
immediately frozen in cold isopentane and stored at 2808C.
SN cryosections (Leica CM 3050S, Leica, Nussloch,
Germany) were homogenized in a Tris buffer (Tris–HCl
50 mM, NaCl 150 mM, EDTA 2 mM, EGTA 2 mM, 10%
sucrose) containing 1 mM dithiothreitol, 0.5 mM Na3VO4,
100 nM okadaic acid and protease inhibitors (Roche Pharma)
and centrifuged at 130 000g for 1 h at 48C. Protein concentration
was determined by the BCA Protein Assay Kit (Pierce, Rock-
ford, IL, USA). Equal amounts of protein (50 mg) were loaded
onto 15% SDS–PAGE, followed by the transfer of proteins
onto a nitrocellulose membrane (Bio-Rad). A sheep anti-a-syn
antibody (AB5334P, Chemicon, Temecula, CA, USA) recogniz-
ing both human and rat a-syn was used to assess the level of
expression of the transgenewhen comparedwith the endogenous
protein. The amount of protein loaded was checked on the same
membrane with an anti-actin antibody (sc-1616, Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Detection and quantification
were performed using the Odysseyw Infrared Imaging System.
Immunohistological analyses and counting
Eight weeks post-injection, rats were deeply anesthetized by
an overdose of pentobarbital and perfused transcardially first
with PBS and then with ice-cold 4% paraformaldehyde
(PFA, Fluka-Sigma, Buchs SG, Switzerland). Brains were
kept for 90 min in 4% PFA and then transferred to 25%
sucrose. Twenty-five mm-thick coronal sections from both
the SN and the striatum were harvested on a sliding microtome
(Leica SM2400; Leica) at a temperature of 2208C. Slices
were then processed for immunohistological treatment.
For immunofluorescence studies, slices were washed in PBS
before blocking in a solution of 10% normal donkey serum
(NDS) (Jackson ImmunoResearch, Suffolk, UK), 1% albumin
from bovine serum (BSA, Fluka-Sigma) and 0.1% Triton
X-100 in PBS, during 2 h at room temperature. Slices were
then incubated overnight at 48C with the primary antibodies
in blocking buffer and subsequently incubated for 2 h at room
temperature in a mix of secondary antibodies conjugated with
488- and/or 568-Alexa Fluor dyes (Molecular Probes, Invitro-
gen AG, Basel, Switzerland) and 1% NDS, previously centri-
fuged at 10 000g for 20 min at 48C. Slices were finally
washed and mounted on glass slides using a DABCO-glycerol
mounting solution. The primary antibodies used in this study
are: anti-human a-syn monoclonal antibody (LB509; Zymed,
San Francisco, CA, USA), anti-a-syn phosphorylated at
Ser129 (1), anti-lamin-B (sc-6217, Santa Cruz Biotechnology),
anti-cleaved caspase-9 (rat-specific, Asp353; Cell Signaling
Technology, Beverly, MA, USA), anti-Bax (6A7; BD Bio-
sciences, Clontech, San Diego, CA, USA), anti-TH (Chemicon)
and anti-VMAT2 (AB1767, Chemicon). Double immunofluor-
escence staining was performed by simultaneous incubation
of sections with the two primary antibodies, followed by the
two secondary antibodies. For double a-syn-thioflavin S
(ThioS) staining, a-syn immunofluorescent staining was pre-
ceded by the following steps: slices were washed in water, incu-
bated for 20 min in 0.05% ThioS diluted in 50% ethanol and
filtered, differentiated in three washes of 5 min each in 80%
ethanol and finally extensively washed in PBS. Dapi staining
was performed by incubating the slices in 40,6-diamidino-
2-phenylindole (Dapi) at a concentration of 1 mg/ml diluted in
water for 12 min followed by substantial washing in PBS.
Percentage of neurons positive for dopaminergic markers
[use of an anti-TH antibody (1:500) and an anti-VMAT2 anti-
body (1:2500)] relative to the contralateral non-injected side
was determined by counting 24 coronal sections (one in six
sections) throughout the SN, under a light microscope
(Olympus CX41) at a magnification of 200#. Striatal dopa-
minergic innervation was analyzed by quantifying the OD of
TH- and VMAT2-immunoreative terminals in 16 (one in six
sections) striatal sections, relative to the contralateral non-
injected hemisphere. These sections were scanned using a
Nikon Super Coolscan 4000 scanner, and the OD of the
tissue (OD that corresponds to the integrated density of gray
values of pixels with correction for non-specific background)
was analyzed using the ImageJ software (free NIH software:
http://rsb.info.nih.gov/ij/). ODs were measured bilaterally
through all the striatum, and arbitrary units were assigned.
The number of ThioS-positive aggregates per mm2 was
obtained by counting two sections at an antero-posterior coor-
dinate of 25.2 (bregma coordinates), at a 40# magnification.
All analyses were performed in a blinded fashion.
For the staining of human a-syn resistant to PK, slices were
first washed in PBS and mounted on Superfrost Plus glass
slides (Menzel-Glaser GmbH&Co KG, Braunschweig,
Germany). Dried mounted slices were incubated for 15 min
in PK 10 mg/ml diluted in 0.1 M Tris–HCl buffer, pH 7.5,
5 mM EDTA at room temperature. After PBS washes, slices
were quenched with 0.1% phenylhydrazine (Merck, White-
house Station, NJ, USA) in PBS at 378C for 1 h and incubated
for 2 h at room temperature in a blocking solution of 10%
horse serum (HS) [Amimed (Bioconcept), Switzerland], 1%
BSA (Fluka-Sigma) and 0.1% Triton X-100 (Sigma) in PBS.
Overnight incubation with an anti-human a-syn monoclonal
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antibody (LB509; Zymed) in blocking buffer at 48C was fol-
lowed by a 2 h incubation with biotinylated goat anti-rabbit
immunoglobulins (Vector Laboratories, Burlingame, CA,
USA) and subsequently by incubation in avidin–biotin–
peroxidase solution (Vector Laboratories) for 30 min. Slices
were finally revealed with 3,30-diaminobenzidine solution
(DAB) (Pierce) and mounted on glass slides.
Image processing and analysis
Observations, counting and brightfield image acquisition were
obtained on a Leica DMI 4000 microscope (software: Leica
LAS) using an Olympus AX70 color camera. The three-
dimensional images were recorded on a Leica DMR XA2
motorized upright confocal microscope (software LCS 2).
They were deconvolved with the commercial image restor-
ation software Huygens 2.8 (Scientific Volume Imaging,
Hilversum, The Netherlands) and visualized with the Imaris
6 software package (Bitplane AG, Zu¨rich, Switzerland).
Quantitative image analyses were performed by processing
the three-dimensional multi-channel images with a dedicated
image-analysis software that we have developed for our
study. This software contains the following three-dimensional
image-processing tools: denoising by Gaussian filtering, auto-
matic threshold using the fluorescence background as baseline,
a connected-component labeling and a function that evaluates
the distance of each voxel to the closest detected border. All
the multi-channel interaction measurements were collected
in a spreadsheet for further statistical analysis. The software
‘Volumetric Segmentation’ was developed as a Java plugin
for the public domain image-processing software, ImageJ
1.37 (National Institutes of Health, Bethesda, MD, USA); it
is available online at: http://bigwww.epfl.ch/sage/soft/volume-
tricsegm/.
Immuno-electron microscopy
Eight weeks post-injection, rats destined to IEM analyses were
deeply anesthetized by an overdose of pentobarbital and per-
fused transcardially first with 0.9% NaCl and then with
ice-cold 4% PFA (Fluka-Sigma). Brains were rapidly
removed and kept in 4% PFA overnight. Thirty mm-thick
coronal sections from the SN were harvested on a sliding
microtome (Leica SM2400; Leica) at a temperature of
2208C. Slices were then treated as described previously
(102). The secondary antibody was an F(ab’)2 fragment of
goat anti-mouse from AURION Ultra Small Immunogold
Reagents. Ultrastructural studies were performed on ultrathin
sections (40 nm), stained with uranyl acetate and Reynold’s
lead citrate and viewed with a Philips CM-100 TEM electron
microscope.
Statistical analyses
The Statistica program (StatSoft, France) was used for all
calculations. One-way analysis of variance (103), followed
by Scheffe´’s post hoc test, revealed a main group effect in
all cases.
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